

REFERENCES

1. Danaei G, Finucane MM, Lu Y, et al: National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. *Lancet* 378: 31, 2011. [PMID: 21705069]
2. http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf (World Health Organization: Global Report on Diabetes, 2016.) Accessed on February 9, 2018.
3. <https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf> (Centers for Disease Control and Prevention: National Diabetes Statistics Report, 2017. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services; 2017.) Accessed November 25, 2017.
4. Forst T, Heise T, Plum-Morschel L: Pharmacological intervention in type 2 diabetes mellitus: a pathophysiologically reasoned approach? *Curr Diabetes Rev* 12: 429, 2016. [PMID: 27296043]
5. American Diabetes Association: Diagnosis and classification of diabetes mellitus. *Diabetes Care* 32(Suppl 1): S62, 2009. [PMID: PMC2613584]
6. Cerf ME: Beta cell dysfunction and insulin resistance. *Front Endocrinol* 4: 37, 2013. [PMID: PMC3608918]
7. Bagger JJ, Knop FK, Lund A, et al: Impaired regulation of the incretin effect in patients with type 2 diabetes. *J Clin Endocrinol Metab* 96: 737, 2011. [PMID: 21252240]
8. Petrie JR: The cardiovascular safety of incretin-based therapies: a review of the evidence. *Cardiovasc Diabetol* 12: 130, 2013. [PMID: 24011363]
9. Paneni F, Beckman JA, Creager MA, Cosentino F: Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. *Eur Heart J* 34(31): 2436, 2013. [PMID: 23641007]
10. Karaca Ü, Schram MT, Houben AJ, Muris DM, Stehouwer CD: Microvascular dysfunction as a link between obesity, insulin resistance and hypertension. *Diabetes Res Clin Pract* 103(3): 382, 2014. [PMID: 24438874]
11. Hodgson K, Morris J, Bridson T, Govan B, Rush C, Ketheesan N: Immunological mechanisms contributing to the double burden of diabetes and intracellular bacterial infections. *Immunology* 144: 171, 2015. [PMID: 25262977]
12. Lipsky BA, Berendt AR, Cornia PB, et al: 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. *Clin Infect Dis* 54: e132, 2012. [PMID: 22619242]
13. Lipsky BA, Aragón-Sánchez J, Diggle M, et al: IWGDF guidance on the diagnosis and management of foot infections in persons with diabetes. *Diabetes Metab Res Rev* 32(suppl 1):45, 2016. [PMID: 26386266]
14. Markakis K, Bowling FL, Boulton AJ: The diabetic foot in 2015: an overview. *Diabetes Metab Res Rev* 32(suppl 1): 169, 2016. [PMID: 26451519]
15. Lipsky BA: Diabetic foot infections: current treatment and delaying the "post-antibiotic era." *Diabetes Metab Res Rev* 32(suppl 1): 246, 2016. [PMID: 26452233]
16. Mandell JC, Khurana B, Smith JT, Czuczman GJ, Ghazikhanian V, Smith SE: Osteomyelitis of the lower extremity: pathophysiology, imaging, and classification, with an emphasis on diabetic foot infection. *Emerg Radiol* 2017 Oct 20. doi: 10.1007/s10140-017-1564-9. [Epub ahead of print] [PMID:29058098]
17. Lauri C, Tamminga M, Glaudemans AWJM, et al: Detection of osteomyelitis in the diabetic foot by imaging techniques: a systematic review and meta-analysis comparing MRI, white blood cell scintigraphy, and FDG-PET. *Diabetes Care* 40: 1111, 2017. [PMID: 28733376]
18. Dhawan B, Soni R, Singh R, Vig V: Endocapsular hematoma: a rare form of ocular hemorrhage after thrombolysis with streptokinase. *N Am J Med Sci* 6: 425, 2014. [PMID: 25210679]
19. Peyman M, Subrayan V: Irreversible blindness following intravenous streptokinase. *JAMA Ophthalmol* 131: 1368, 2013. [PMID: 23929315]
20. Mahaffey KW, Granger CB, Toth CA, et al: Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. *J Am Coll Cardiol* 30: 1606, 1997. [PMID: 9385883]
21. Demaerschalk BM, Kleindorfer DO, Adeoye OM, et al: Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 47: 581, 2016. [PMID: 26696642]
22. Van de Werf F, Bax J, Betriu A, et al: Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. *Eur Heart J* 29: 2909, 2008. [PMID: 19004841]
23. American Diabetes Association: Classification and diagnosis of diabetes. *Diabetes Care* 40(suppl 1): S11, 2017. [PMID: 27979889]
24. Garber AJ, Abrahamson MJ, Barzilay JL, et al: Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm: 2017 executive summary. *Endocr Pract* 23: 207, 2017. [PMID: 28095040]
25. American Diabetes Association: Glycemic targets. *Diabetes Care* 40(suppl 1): S48, 2017. [PMID: 27979893]
26. Umpierrez GE, Hellman R, Korytkowski MT, et al: Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab* 97: 16, 2012. [PMID: 22223765]
27. American Diabetes Association: Diabetes care in the hospital. *Diabetes Care* 40(suppl 1): S120, 2017. [PMID: 27979901]
28. Umpierrez GE, Pasquel FJ: Management of inpatient hyperglycemia and diabetes in older adults. *Diabetes Care* 40: 509, 2017. [PMID: 28325798]
29. Maruthur NM, Tseng E, Hutless S, et al: Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. *Ann Intern Med* 164: 740, 2016. [PMID: 27088241]
30. Barry MJ, Humphrey LL, Qaseem A: Oral pharmacologic treatment of type 2 diabetes mellitus. *Ann Intern Med* 167: 75, 2017. [PMID: 28672387]
31. Raz I: Guideline approach to therapy in patients with newly diagnosed type 2 diabetes. *Diabetes Care* 2: S139, 2013. [PMID: 23882038]
32. Lecka-Czernik B: Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis. *Curr Osteoporos Rep* 8: 178, 2010. [PMID: 20809203]
33. Madsbad S: Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. *Diabetes Obes Metab* 18: 317, 2016. [PMID: 26511102]
34. Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ: Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. *Diabetes Obes Metab* 19: 524, 2017. [PMID: 27981757]
35. Østergaard L, Frandsen CS, Madsbad S: Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review. *Exp Rev Clin Pharmacol* 9: 241, 2016. [PMID: 26573176]
36. Chaudhury A, Duvoor C, Reddy Dendi VS, et al: Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management. *Front Endocrinol (Lausanne)* 8: 6, 2017. [PMID: 28167928]
37. Qaseem A, Barry MJ, Humphrey LL, Forcica MA: Clinical Guidelines Committee of the American College of Physicians: Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline update from the American College of Physicians. *Ann Intern Med* 166: 279, 2017. [PMID: 28055075]
38. Tran L, Zielinski A, Roach AH, et al: Pharmacologic treatment of type 2 diabetes: oral medications. *Ann Pharmacother* 49: 540, 2015. [PMID: 25667196]
39. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB: Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. *Diabetes Care* 38: 1687, 2015. [PMID: 26078479]
40. Martens P, Tits J: Approach to the patient with spontaneous hypoglycemia. *Eur J Intern Med* 25: 415, 2014. [PMID: 24641805]
41. Kittah NE, Vella A: Management of endocrine disease: pathogenesis and management of hypoglycemia. *Eur J Endocrinol* 177: R37, 2017. [PMID: 28381450]
42. Kandaswamy L, Raghavan R, Pappachan JM: Spontaneous hypoglycemia: diagnostic evaluation and management. *Endocrine* 53: 47, 2016. [PMID: 26951054]
43. Cryer PE, Axelrod L, Grossman AB, et al: Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab* 94: 709, 2009. [PMID:19088155]
44. Seaquist ER, Anderson J, Childs B, et al: Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. *Diabetes Care* 36: 1384, 2013. [PMID: 23589542]
45. Glatstein M, Scolnik D, Bentur Y: Octreotide for the treatment of sulfonyleurea poisoning. *Clin Toxicol (Phila)* 50: 795, 2012. [PMID: 23046209]
46. Ford W, Self WH, Slovis C, McNaughton CD: Diabetes in the emergency department and hospital: acute care of diabetes patients. *Curr Emerg Hosp Med Rep* 1: 1, 2013. [PMID: 23997994]